Pelvic organ prolapse (POP)—the descent of the bladder, uterus, or rectum into the vaginal canal—affects nearly one in four women in the United States. For decades, diagnosis has relied on physical examination and symptom reporting. But beneath the surface, a microscopic story is unfolding. At the heart of POP lies collagen, the primary structural protein responsible for pelvic support. And new research suggests that specific collagen markers may hold the key to earlier diagnosis, better treatment selection, and even prevention.
This article explores the science of collagen markers in POP, from nanoscopic fibril abnormalities to emerging blood-based biomarkers, and how these discoveries are transforming women’s pelvic health.
Part 1: Why Collagen Matters for Pelvic Support
The pelvic floor is a complex hammock of muscles, ligaments, and connective tissue. But the true workhorse of structural support is collagen—specifically Type I and Type III collagen .
| Collagen Type | Role in Pelvic Floor | Proportion in Healthy Tissue |
|---|---|---|
| Type I Collagen (COLI) | Provides high tensile strength and stiffness; the “backbone” of support | ~70-80% |
| Type III Collagen (COLIII) | Provides flexibility and distension; allows tissue to stretch and recoil | ~20-30% |
In healthy pelvic connective tissue, these two collagen types exist in a delicate balance. Fibroblasts (the cells that produce collagen) continuously synthesize new collagen fibers while matrix metalloproteinases (MMPs) break down old or damaged ones . This constant remodeling keeps the pelvic floor strong yet flexible.
But in women with POP, this balance shatters.
Part 2: What Goes Wrong? The Collagen Defects in POP
Research over the past decade has identified a constellation of collagen abnormalities in women with POP. These changes occur at multiple scales—from molecular composition to nanoscopic structure to overall tissue mechanics.
2.1 Altered Collagen Ratios
One of the most consistent findings is a dramatic shift in the Type I to Type III collagen ratio. While healthy tissue maintains a COLI:COLIII ratio of approximately 3:1, POP tissue often shows a ratio that is doubled—meaning proportionally more Type I collagen relative to Type III .
At first glance, more Type I collagen (the “strong” collagen) might seem beneficial. But the reality is more complex. The increase in COLI relative to COLIII reflects disordered remodeling, not improved strength. The newly deposited collagen fibers are often disorganized, fragmented, and functionally inferior .
2.2 Reduced Total Collagen Content
Despite the shift in ratios, the total amount of collagen in POP-affected vaginal tissue is significantly reduced compared to healthy controls . Masson’s trichrome staining and Sirius Red staining—both standard histological techniques—consistently show lighter staining in POP tissue, indicating less collagen overall .
2.3 Nanoscopic Fibril Abnormalities
Using atomic force microscopy (AFM), researchers have identified distinct nanoscopic abnormalities in POP collagen fibrils :
| Feature | Healthy Collagen | POP Collagen |
|---|---|---|
| Fibril width | Uniform, consistent | Bulkier, more uneven |
| D-period (periodic banding pattern) | Regular (~67 nm) | Aberrant, reduced |
| Fibril stiffness | Normal | Significantly stiffer |
| Alignment | Organized network | Disorganized, loose |
The D-period is particularly important. This 67-nanometer repeating pattern is a signature of properly assembled collagen fibrils. When the D-period is abnormal, the fibrils cannot pack together correctly, resulting in a “loose and fragile fiber network accountable for the weak load-bearing capability” .
2.4 Imbalanced Enzyme Activity
Collagen metabolism is regulated by two opposing enzyme families:
- Matrix Metalloproteinases (MMPs): Break down collagen (MMP-2 and MMP-9 are the primary players)
- Tissue Inhibitors of Metalloproteinases (TIMPs): Inhibit MMP activity
In POP, multiple studies have documented increased MMP expression alongside decreased TIMP activity . This imbalance tips the scale toward collagen degradation, contributing to tissue weakening.
A 2025 study found that MMP-2 expression is significantly elevated in POP patients, with a corresponding decrease in Collagen I levels . The same study identified JAM-2 (Junctional Adhesion Molecule 2) as a novel marker, with reduced expression in POP tissue.
Part 3: Key Collagen Markers for POP Diagnosis
Researchers have identified several molecular markers that could serve as diagnostic tools for POP. These markers fall into three categories: structural proteins, regulatory molecules, and enzymes.
3.1 Structural Markers
| Marker | Change in POP | Diagnostic Potential |
|---|---|---|
| Collagen I (COLI) | Decreased | Core marker of tissue integrity |
| Collagen III (COLIII) | Decreased (relative to COLI) | Ratio shift indicates remodeling defect |
| COLI:COLIII Ratio | Increased (~2x normal) | Most consistent biochemical marker |
| Elastin | Decreased | Contributes to tissue laxity |
3.2 Regulatory Markers
A landmark 2025 study published in Scientific Reports demonstrated that IGF-1 significantly enhances collagen production in POP fibroblasts through the PI3K/AKT signaling pathway, with LARP6 acting as a critical mediator . When researchers knocked down LARP6 using siRNA technology, collagen secretion was dramatically reduced—confirming its central role.
3.3 Enzymatic Markers
| Marker | Change in POP | Role |
|---|---|---|
| MMP-2 | Increased | Degrades Type IV collagen and gelatin |
| MMP-9 | Increased | Degrades Type I and III collagen |
| TIMP-1 | Decreased | Inhibits MMP activity |
| MMP:TIMP Ratio | Increased | Indicates net collagen degradation |
A 2024 study using a murine POP model found that the HIF-1α inhibitor PX-478 could reduce MMP-2 and MMP-9 expression while increasing TIMP-1, suggesting potential therapeutic applications .
Part 4: From Research to Reality—Diagnostic Applications
The ultimate goal of collagen marker research is to develop non-invasive or minimally invasive diagnostic tools. Several approaches are emerging.
4.1 Tissue Biopsy Analysis (Current Standard)
Currently, collagen marker assessment requires a vaginal wall tissue biopsy obtained during surgery. Immunohistochemistry (IHC) and Western blotting are used to quantify COLI, COLIII, and MMP expression .
Limitations: Invasive, requires surgery, cannot be used for screening.
4.2 POP-Q Score as a Collagen Proxy
Interestingly, researchers have found that the POP Quantification (POP-Q) system—a standard clinical tool that measures prolapse severity using points like C (cervical descent)—correlates strongly with underlying collagen abnormalities .
As prolapse severity increases (higher POP-Q scores), the following collagen changes become more pronounced:
- Stiffer collagen fibrils
- Reduced D-period
- Increased fibril alignment
- Imbalanced COLI:COLIII ratio
This suggests that a simple clinical examination may provide indirect information about collagen health. However, POP-Q cannot detect early, pre-symptomatic collagen abnormalities.
4.3 Blood-Based Biomarkers (Emerging)
The holy grail is a simple blood test. Recent studies have begun exploring whether circulating levels of collagen-related proteins correlate with POP severity.
A 2025 study examining JAM-2, Collagen I, and MMP-2 used ELISA (enzyme-linked immunosorbent assay) to measure these markers in blood samples. ROC analysis demonstrated “significant discriminative power” for diagnosing POP, with substantial area under the curve (AUC) values .
What this means: A blood test for POP may be possible within the next 5-10 years. Women could potentially be screened for collagen abnormalities long before prolapse becomes symptomatic.
4.4 Nanoscopic Imaging (Research Tool)
Advanced imaging techniques like atomic force microscopy (AFM) can detect nanoscale collagen abnormalities in tissue samples . While not practical for routine clinical use, AFM has been instrumental in identifying the D-period and fibril stiffness as diagnostic markers.
Part 5: Therapeutic Implications—Can We Fix Collagen?
If collagen defects drive POP, then collagen-targeted therapies could potentially treat or even prevent prolapse.
5.1 Platelet-Rich Plasma (PRP) Therapy
PRP contains growth factors (including IGF-1 and TGF-β) that stimulate collagen production. A 2025 clinical trial (NCT07150442) is currently investigating whether PRP injection during POP surgery can improve the COLI:COLIII ratio and reduce recurrence .
Trial design: Patients undergoing POP reconstructive surgery receive either PRP (derived from their own blood) or placebo (saline) injected into the anterior vaginal wall. Biopsies are taken during surgery and again at 8 weeks post-op to measure collagen ratio changes .
Results pending—but early in vitro studies are promising.
5.2 IGF-1 Based Therapies
Given that IGF-1 upregulates LARP6 and collagen production via the PI3K/AKT pathway, researchers are exploring whether IGF-1 analogs or pathway activators could restore collagen synthesis in POP patients .
5.3 HIF-1α Inhibition
In a murine POP model, the HIF-1α inhibitor PX-478 (administered intravaginally) reduced vaginal length, attenuated fibrosis, and restored Type I and Type III collagen fibers . The treatment also reduced M1 and M2 macrophage markers and suppressed IL-18 secretion, suggesting an anti-inflammatory effect.
5.4 Ascorbic Acid (Vitamin C) Releasing Membranes
A 2025 study from the University of Helsinki tested ascorbic acid 2-phosphate (A2P)-releasing PLCL membranes in a rat model. A2P (a stable form of Vitamin C) is a necessary cofactor for collagen synthesis. The results showed that A2P-releasing membranes “enhanced tissue strength without increased stiffness, compensating for material degradation through tissue regeneration” .
Clinical potential: These absorbable membranes could be used during POP repair surgery to promote native tissue regeneration, potentially replacing problematic synthetic meshes.
5.5 Exosome-Based Therapy
A 2024 study demonstrated that exosomes from umbilical cord mesenchymal stromal cells promote collagen production in POP patient fibroblasts. The exosomes were internalized by vaginal fibroblasts and stimulated collagen synthesis through specific microRNA cargo .
Why this matters: Exosome therapy could potentially be delivered via injection to restore collagen without surgery.
Part 6: Can Collagen Markers Predict Prolapse Progression?
One of the most exciting questions is whether collagen markers can identify women at risk for POP before symptoms develop.
The nanoscopic abnormalities identified by Kim et al.—bulkier, stiffer fibrils with aberrant D-period—were present in surgical tissue from POP patients, but it is unknown whether these changes precede or result from prolapse .
However, the correlation between POP-Q scores and collagen severity suggests a progressive relationship. As prolapse worsens, so does collagen disorganization . This raises the possibility that early intervention (pelvic floor therapy, pessary use) might slow or prevent collagen deterioration.
Part 7: Current Commercial Landscape
As of 2025, there are no FDA-approved blood tests for collagen markers in POP. Collagen marker assessment remains a research tool.
However, several related products are available for consumers interested in pelvic health:
| Product Category | What It Does | Affiliate Link |
|---|---|---|
| Collagen Supplements (Hydrolyzed) | Supports general skin, joint, and connective tissue health | Search on Amazon → |
| Vitamin C Supplements | Essential cofactor for collagen synthesis | Search on Amazon → |
| Pelvic Floor Trainers (Elvie, Perifit) | Strengthen pelvic floor muscles to support prolapse | Search on Amazon → |
| Vaginal Estrogen Creams (OTC) | Supports tissue health in menopause | Search on Amazon → |
| Vaginal Pessaries (Support Devices) | Non-surgical prolapse management | Search on Amazon → |
Important: Collagen supplements are not proven to reverse POP collagen defects. The abnormal collagen in POP is not due to dietary deficiency but to cellular dysfunction (reduced fibroblast activity, increased MMPs). Always consult a healthcare provider before starting any supplement.
Part 8: The Bottom Line—What This Means for You
| If you are… | What collagen markers mean for you |
|---|---|
| Asymptomatic with risk factors (multiple vaginal deliveries, age >50, family history) | Future blood tests may screen for collagen abnormalities before prolapse develops. For now, focus on prevention: pelvic floor exercises, avoid heavy straining, maintain healthy weight. |
| Symptomatic with mild POP | Your collagen abnormalities are likely mild to moderate. Pelvic floor physical therapy and pessary use may slow progression. Discuss collagen-targeted therapies (PRP, exosomes) with a urogynecologist if available. |
| Scheduled for POP surgery | Ask your surgeon about PRP injection during repair (clinical trial availability). Consider that underlying collagen defects may increase recurrence risk—lifestyle modifications and postoperative pelvic floor therapy are essential. |
| Recurrent POP after surgery | You may have a more severe collagen disorder. Genetic testing for connective tissue disorders (Ehlers-Danlos syndrome, Marfan syndrome) may be appropriate. Seek a specialized pelvic reconstructive surgeon. |
Summary Table: Collagen Markers at a Glance
References (Key Studies Cited)
- Xu LM, Yu XX, Zhang N, Chen YS. Exosomes from umbilical cord mesenchymal stromal cells promote the collagen production of fibroblasts from pelvic organ prolapse. World J Stem Cells. 2024;16(6):708-727.
- Clinical Significance of JAM‐2 Expression in the Vaginal Wall Tissues of Patients With Pelvic Organ Prolapse. J Cell Mol Med. 2025;29(7):e70512.
- IGF-1 regulates LARP6-mediated collagen metabolism in vaginal fibroblasts of POP patients via the PI3K/AKT pathway. Sci Rep. 2025.
- The therapeutic potential of PX-478 in a murine model of pelvic organ prolapse. DOAJ. 2024.
- Distinctive structure, composition and biomechanics of collagen fibrils in vaginal wall connective tissues associated with pelvic organ prolapse. Acta Biomater. 2022;152:335-344.
- Identifying distinct nanoscopic features of native collagen fibrils towards early diagnosis of pelvic organ prolapse. Nanomedicine. 2016;12(3):667-675.
- Ascorbic acid 2-phosphate-releasing poly-l-lactide-co-epsilon-caprolactone membranes enhance tissue regeneration: First in vivo insights for pelvic organ prolapse. Regen Biomater. 2025;12:rbaf097.
- The Effects of Platelet Rich Plasma Adjuvant to Type I/III Collagen Ratio, MMP-2 and MMP-9 in Pelvic Organ Prolapse Repair. ClinicalTrials.gov NCT07150442.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Collagen marker testing for POP is primarily a research tool as of 2025. Always consult a urogynecologist or pelvic floor specialist for diagnosis and treatment of pelvic organ prolapse.
This article contains affiliate links. As an Amazon Associate, the author may earn a commission from qualifying purchases.
